Clene to Present at The Canaccord 46th Annual Growth Conference

Clene (Nasdaq: CLNN) announced that its management will present at the Canaccord 46th Annual Growth Conference and host 1x1 investor meetings.

Rhea-AI Summary

Clene (Nasdaq: CLNN) announced that its management will present at the Canaccord 46th Annual Growth Conference and host 1x1 investor meetings. The late clinical-stage biopharmaceutical company, focused on neurodegenerative diseases such as ALS and MS, is scheduled to present on August 11, 2026 at 10:30 a.m. ET in Boston, MA. A live webcast will be accessible via the Clene website’s Events section, with online registration available for remote viewers.

Argus Jul 29 session 8 alerts

-5.41% close to close 1.6x rel. volume Open Argus

Details

News Market Reaction – CLNN

+6.0% Peak Tracked

-3.2% Trough Tracked

$68.49M Market Cap

In the Jul 29 session, CLNN declined 5.41%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.0% during that session. Argus tracked a trough of -3.2% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.4% in the session following this news. Clene's May 5 conference announcement was ...

Analysis

The stock moved -5.4% in the session following this news. Clene's May 5 conference announcement was followed by a -18.67% 24-hour move. The active S-3 is a resale registration, and recent insider activity was net selling, providing relevant context for risk assessment.

Key Figures

Conference edition: 46th Presentation date: August 11, 2026 Presentation time: 10:30am ET +1 more

Conference edition

46th

Canaccord Annual Growth Conference

Presentation date

August 11, 2026

Canaccord Annual Growth Conference

Presentation time

10:30am ET

August 11, 2026

Investor meetings

1x1

Canaccord Annual Growth Conference

Historical Context

5 past events · Latest: May 14

5 events

1. May 14

   First-quarter earnings

   24h Move

   +8.5%

   First-quarter results and regulatory advances supported a positive 24-hour price reaction.

2. May 05

   Registered direct offering

   24h Move

   -18.7%

   The $7 million offering was followed by an 18.67% negative 24-hour reaction.

3. May 05

   Investor conference presentation

   24h Move

   -18.7%

   A conference participation announcement preceded an 18.67% negative 24-hour reaction.

4. May 04

   FDA pathway update

   24h Move

   +31.8%

   FDA minutes supported a potential accelerated-approval NDA pathway for CNM-Au8.

5. Mar 12

   Full-year earnings

   24h Move

   +6.1%

   Full-year results and operating updates preceded a 6.09% positive 24-hour reaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

amyotrophic lateral sclerosis, multiple sclerosis, neurodegenerative diseases

3 terms

amyotrophic lateral sclerosis medical

"including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)"

A progressive disease in which nerve cells that control voluntary muscles gradually fail, leading to loss of movement, speech and eventually breathing — like an electrical wiring system in the body slowly shorting out. It matters to investors because there are few effective treatments, so clinical trial results, regulatory approvals, new therapies or diagnostics can rapidly change patient care, market opportunity and company valuations.

multiple sclerosis medical

"including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)"

A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.

neurodegenerative diseases medical

"focused on revolutionizing the treatment of neurodegenerative diseases"

Neurodegenerative diseases are conditions where brain or nerve cells progressively lose function and die, causing symptoms like memory loss, movement problems, or cognitive decline — think of the brain’s wiring slowly wearing out. Investors care because these illnesses create sustained demand for treatments, diagnostics, and long-term care, drive regulatory decisions and clinical-trial milestones that move stock prices, and concentrate both high development risk and the potential for large financial returns if effective therapies are approved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 46^th Annual Growth Conference and host 1x1 investor meetings.

Date: August 11, 2026
Time of Presentation: 10:30am ET
Location: Boston, MA

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link.

About Clene
Clene Inc. (Nasdaq: CLNN), along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Clene (CLNN) present at the Canaccord 46th Annual Growth Conference in 2026?

Clene will present on August 11, 2026 at 10:30 a.m. ET. According to Clene, the presentation will take place in Boston, MA as part of the Canaccord 46th Annual Growth Conference.

How can investors access the Clene (CLNN) webcast from the Canaccord 2026 Growth Conference?

Investors can access the webcast through the Events section of the Clene website. According to Clene, viewers may alternatively register online to watch the presentation via the provided webcast link.

Where is Clene (CLNN) presenting during the Canaccord 46th Annual Growth Conference?

Clene is presenting in Boston, MA at the Canaccord 46th Annual Growth Conference. According to Clene, the company’s management will deliver the presentation and host one-on-one investor meetings during the event.

What will Clene (CLNN) management do at the Canaccord 2026 conference?

Clene management will present at the conference and host 1x1 investor meetings. According to Clene, the event offers an opportunity to discuss its late clinical-stage programs in neurodegenerative diseases with investors.

What type of company is Clene (CLNN), presenting at the Canaccord Growth Conference 2026?

Clene is a late clinical-stage biopharmaceutical company focused on neurodegenerative diseases. According to Clene, its work targets conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).